- Home
- NGD vs TMDX Comparison
NGD vs TMDX Comparison
Compare NGD & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGD
- TMDX
- Stock Information
- Founded
- NGD N/A
- TMDX 1998
- Country
- NGD Canada
- TMDX United States
- Employees
- NGD 1607
- TMDX N/A
- Industry
- NGD
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NGD
- TMDX Health Care
- Exchange
- NGD Nasdaq
- TMDX Nasdaq
- Market Cap
- NGD 3.1B
- TMDX 2.3B
- IPO Year
- NGD 2004
- TMDX 2019
- Fundamental
- Price
- NGD $4.03
- TMDX $93.20
- Analyst Decision
- NGD Buy
- TMDX Buy
- Analyst Count
- NGD 3
- TMDX 10
- Target Price
- NGD $4.33
- TMDX $120.11
- AVG Volume (30 Days)
- NGD 27.7M
- TMDX 1.1M
- Earning Date
- NGD 04-29-2025
- TMDX 05-08-2025
- Dividend Yield
- NGD N/A
- TMDX N/A
- EPS Growth
- NGD N/A
- TMDX N/A
- EPS
- NGD 0.17
- TMDX 1.01
- Revenue
- NGD $941,500,000.00
- TMDX $441,540,000.00
- Revenue This Year
- NGD $32.72
- TMDX $25.33
- Revenue Next Year
- NGD $42.38
- TMDX $20.53
- P/E Ratio
- NGD $24.17
- TMDX $92.28
- Revenue Growth
- NGD 21.17
- TMDX 82.74
- 52 Week Low
- NGD $1.74
- TMDX $55.00
- 52 Week High
- NGD $4.21
- TMDX $177.37
- Technical
- Relative Strength Index (RSI)
- NGD 62.29
- TMDX 63.43
- Support Level
- NGD $3.28
- TMDX $89.10
- Resistance Level
- NGD $4.21
- TMDX $95.71
- Average True Range (ATR)
- NGD 0.20
- TMDX 4.15
- MACD
- NGD 0.05
- TMDX -0.23
- Stochastic Oscillator
- NGD 80.53
- TMDX 57.13
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets which are also its operating segments: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.